Bristol-Myers Squibb (BMS) specializes in the manufacturing, marketing, and distribution of biopharmaceuticals. The company operates through a single business segment—Biopharmaceutical which further comprises of two categories namely: prioritized brands and established brands. Under this segment, the company offers a wide variety of products for oncology, cardiovascular, immunoscience, virology, and neuroscience.
Swords Laboratories, the company’s bulk APIs manufacturing site, is involved in the manufacturing of multiple small molecule APIs and intermediates; it is also responsible for the development and launch of all novel small molecule APIs produced by the company.